HXN5003

DRUG2 trials

Sponsors

Helixon Biotechnology (Suzhou) Co., Ltd

Conditions

Atopic DermatitisHealth Adult SubjectsModerate-to-Severe Atopic Dermatitis

Phase 1

A Dose Escalation Phase 1 Study of HXN5003 in Healthy Participants

Not yet recruitingNCT07549750

Helixon Biotechnology (Suzhou) Co., LtdAtopic Dermatitis

Start: 2026-05-27End: 2027-04-16Target: 28Updated: 2026-04-24

A Phase I Study of HXN5003 in Healthy Participants and Patients With Moderate-to-Severe Atopic Dermatitis

Not yet recruitingNCT07801612

Helixon Biotechnology (Suzhou) Co., LtdHealth Adult Subjects, Moderate-to-Severe Atopic Dermatitis

Start: 2026-09-01End: 2028-01-01Target: 68Updated: 2026-09-03